Future directions should include investigation of CD38 expression patterns in human choroid plexus across the lifespan, assessment of CSF NAD+ levels in aging and cognitive impairment, and development of additional brain-penetrant CD38 inhibitors with improved pharmacological properties. The gene discussed is CD38; the disease is Cognitive impairment.